Patent application number | Description | Published |
20100190782 | COMPOUNDS AND METHODS OF USE - In one aspect, the present invention provides for a compound of Formula I | 07-29-2010 |
20100210622 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE - In one aspect, the present invention provides for a compound of Formula I | 08-19-2010 |
20110046066 | INHIBITORS OF IAP - The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula (I), and G, X | 02-24-2011 |
20110077265 | INHIBITORS OF IAP - The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds having the general formula U1-M-U2 wherein M is a linking group covalently joining R2, R3, R4 or R5 of U1 to an R2, R3, R4 or R5 group of U2; U1 and U2 have the general formula (I) and G, X1, X2, R2, R3, R3′, R4, R4′ and R5, are as described herein. | 03-31-2011 |
20110269696 | INHIBITORS OF IAPS - The invention provides novel compounds that are inhibitors of IAPs having the general formula: wherein X | 11-03-2011 |
20120171199 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. | 07-05-2012 |
20120184541 | COMPOUNDS AND METHODS OF USE - In one aspect, the present invention provides for a compound of Formula I | 07-19-2012 |
20130079331 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z | 03-28-2013 |
20130324516 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES - The invention provides novel compounds having the general formula: | 12-05-2013 |
20140058098 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z | 02-27-2014 |
20140135308 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z | 05-15-2014 |
20140288047 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE - Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z | 09-25-2014 |
20140323478 | SERINE/THREONINE KINASE INHIBITORS - Compounds having the formula I, or a pharmaceutically acceptable salt thereof, wherein R | 10-30-2014 |
20150031674 | SERINE/THREONINE KINASE INHIBITORS - Compounds having the formula I wherein R | 01-29-2015 |
20150079081 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE - Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. | 03-19-2015 |